CAM
RPRX icon

ClariVest Asset Management’s Royalty Pharma RPRX Stock Holding History

ClariVest Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$1.29K Hold
49
– – ﹤0.01% 584
2024
Q2 		$1.29K Buy
+49
New +$1.36K ﹤0.01% 584

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClariVest Asset Management's RPRX Position: Q3 2024 in Review

ClariVest Asset Management held its Royalty Pharma (RPRX) position steady in Q3 2024 at 49 shares worth $1.29K. The position accounts for ﹤0.01% of the portfolio, ranked #584.

ClariVest Asset Management first reported a position in RPRX in Q2 2024 and has held it in 2 quarters since. 395 funds tracked by Wall St. Rank hold RPRX as of Q3 2024.

  • ClariVest Asset Management held 49 shares of Royalty Pharma worth $1.29K as of Q3 2024.
  • ClariVest Asset Management left its Royalty Pharma share count unchanged in Q3 2024.
  • Royalty Pharma made up ﹤0.01% of ClariVest Asset Management's portfolio in Q3 2024, its #584 holding.
  • ClariVest Asset Management first reported a position in Royalty Pharma in Q2 2024 and has held it in 2 quarters since.
  • 395 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2024.

Based on ClariVest Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.